Although the TAM inhibitor sitravatinib failed to improve outcomes in unselected NSCLC patients when added to immunotherapy [36], TYRO3 amplification may identify a subset of SCLC patients who could benefit from TAM-targeted therapies [37]. This evidence concerns the gene TYRO3 and non-small cell lung carcinoma.